Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Computershare Trustees (Jersey) Limited as trustee of the Schroders Employee Benefit Trust (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. Fo...

LONDON--(BUSINESS WIRE)--Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The...

PARIS--(BUSINESS WIRE)--Havas reports the progress of transactions under its current share buyback program....

NEW ORLEANS--(BUSINESS WIRE)--Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest dur...

PORTO, Portugal--(BUSINESS WIRE)--Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditions are among the leading causes of death. Following...

PARIS--(BUSINESS WIRE)--Reply [EXM, STAR: REY] nimmt an der VivaTech 2026 teil, Europas größter Messe für Innovation und Technologie, die vom 17. bis 20. Juni im Paris Expo Porte de Versailles stattfindet. Dort präsentiert das Unternehmen die neuesten Entwicklungen in den Bereichen KI-gestütztes Software Engineering, intelligente Customer Experiences, Daten & KI sowie industrielle KI. Künstliche Intelligenz (KI), autonome Agenten, Robotik und neue digitale Erlebnisse verändern ganze Branche...

PARIS--(BUSINESS WIRE)--Reply [EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond exper...

PARIGI--(BUSINESS WIRE)--Reply [EXM, STAR: REY] partecipa a VivaTech 2026, il più grande evento europeo dedicato all’innovazione e alla tecnologia, in programma dal 17 al 20 giugno presso il Paris Expo Porte de Versailles. Durante l’evento, Reply presenterà alcune delle ultime innovazioni in ambito AI per il software engineering, AI-powered experiences, data & AI, e industrial AI. Le industrie stanno cambiando volto sotto la spinta dell’AI, degli agenti autonomi, della robotica e delle nuov...

PARIS--(BUSINESS WIRE)--Reply [EXM, STAR: REY] participe à VivaTech 2026, le plus grand événement européen dédié à l’innovation et à la technologie, qui se tiendra du 17 au 20 juin au Paris Expo Porte de Versailles. À cette occasion, Reply présentera ses dernières innovations dans les domaines de l’IA appliquée à l’ingénierie logicielle, des expériences enrichies par l’IA, de la data et de l’IA, ainsi que de l’IA industrielle. Les secteurs d’activité sont en pleine transformation sous l’effet d...

LJUBLJANA, Slowenien--(BUSINESS WIRE)--Cosylab gab heute die Markteinführung von PlanOne™ bekannt, einem Bestrahlungsplanungssystem für die Teilchentherapie, das physikalisch präzise, radiobiologisch fundierte Planung und einen einheitlichen klinischen Arbeitsablauf in einer einzigen Umgebung vereint. PlanOne™ verfügt über die FDA-Zulassung (510(k)-Freigabe). „Am Anfang von PlanOne™ stand das Zuhören. Durch unsere langjährige Arbeit an Steuerungssystemen in der Radioonkologie standen wir in dir...